Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397115 | 0.94 | GRM5 (0.33) | GRM5PKMCYP11B1CYP11B2 | |
| SCHEMBL23540770 | 0.84 | TLR9 (0.34) | GRM5 | |
| SCHEMBL31397182 | 0.83 | BRD4 (0.32) | GRM5 | |
| SCHEMBL31397611 | 0.81 | LRRK2 (0.38) | GRM5PIK3CAPRKDC | |
| SCHEMBL31397340 | 0.81 | PKM (0.34) | GRM5PKMPIK3CAPRKDCCYP11B1 | |
| SCHEMBL31397302 | 0.81 | PIK3CA (0.32) | PIK3CA | |
| SCHEMBL31397484 | 0.80 | MAPT (0.38) | GRM5PKMPIK3CAPRKDC | |
| SCHEMBL31397431 | 0.78 | FFAR1 (0.38) | GRM5PKM | |
| SCHEMBL31397527 | 0.78 | FFAR1 (0.36) | GRM5PKMPIK3CAPRKDCPDCD1 | |
| SCHEMBL23540601 | 0.78 | BRD4 (0.34) | GRM5PKMPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | GRM5 3439/4885PKM 1599/4885PIK3CA 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.